SecBot SecBot

DVAX

DYNAVAX TECHNOLOGIES CORP
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001029142 Biotech & Drug Discovery
No price
Insider net
$0
no open-market trades · since Feb 10
New fund stakes
0
Q1 2026 13F · 21 exits

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Feb 10. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q1 2026: 0 added (0 new), 21 trimmed or exited.

Who's buying

13F· Q1 2026
0
new positions
21
exits

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Dec 2025
Recent actions
DateFirmActionRating
Dec 24, 2025William Blair
DOWNGRADE
DOWNGRADEMarket Perform
Aug 22, 2025JMP Securities
REITERATE
REITERATEMarket Outperform
Aug 8, 2025JMP Securities
MAINTAIN
MAINTAINMarket Outperform
May 7, 2025JMP Securities
MAINTAIN
MAINTAINMarket Outperform
Apr 17, 2025Goldman Sachs
MAINTAIN
MAINTAINSell
Feb 21, 2025Citizens Capital Markets
MAINTAIN
MAINTAINMarket Outperform

Insider ledger

Form 4
$0
open-market buys or sells · since Feb 10
DateInsiderTypeValue
Feb 10, 2026
Spencer Ryan
CEO and Director
Feb 10, 2026
TO ISSUER130,000 sh
Feb 10, 2026
SILVERNAIL LAUREN P
Director
Feb 10, 2026
TO ISSUER7,125 sh
Feb 10, 2026
Myers Scott Dunseth
Director
Feb 10, 2026
TO ISSUER31,204 sh
Feb 10, 2026
Myers Scott Dunseth
Director
Feb 10, 2026
TENDER3,800 sh
Feb 10, 2026
MacDonald Kelly
SVP and CFO
Feb 10, 2026
TO ISSUER100,000 sh
Feb 10, 2026
MacDonald Kelly
SVP and CFO
Feb 10, 2026
TO ISSUER65,000 sh
Feb 10, 2026
MacDonald Kelly
SVP and CFO
Feb 10, 2026
TO ISSUER70,000 sh
Feb 10, 2026
MacDonald Kelly
SVP and CFO
Feb 10, 2026
TO ISSUER28,283 sh

Washington

Corporate Lobbying

15 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 8, 2026 Clinical trial readout
T-90d Trial Readout: rF1V-1018 (Phase 2)
Trial: Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Mar 31, 2026 Inst.
BlackRock, Inc. · EXIT
0 shares ($0.00)
Mar 31, 2026 Inst.
STATE STREET CORP · EXIT
0 shares ($0.00)
Feb 10, 2026 Insider
Spencer Ryan disposed of 130,000 shares
CEO and Director
Feb 10, 2026 Insider
SILVERNAIL LAUREN P disposed of 7,125 shares
Director
Feb 10, 2026 Insider
Myers Scott Dunseth disposed of 31,204 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent